Opinion

Video

Novel Combination Regimens for 2L mCRC: Insights from ASCO 202

The panel examines data from the ZL-IRIAN study and Phase II study, which provide insights into second-line treatment options for patients with metastatic colorectal cancer.

  1. Dr Cohen:ZL-IRIAN study (NCT05229003; Wang C, et al. ASCO 2024. Abstract 3570)– Irinotecan plus anlotinib ± penpulimab in 2L mCRC
  2. Dr Ciombor: Ph II study (Zhao W, et al. ASCO 2024. Abstract 3571) – fruquintinib plus investigator choice of chemotherapy in 2L mCRC

Related Videos
Jonathan C. Trent, MD, PhD
5 KOLs are featured in this panel.
5 KOLs are featured in this panel.
2 KOLs are featured in this panel.
2 KOLs are featured in this panel.
Video 6 - 2 KOLs are featured in, "Other trials of note investigating targeted therapies in later line HR+/HER2- mBC"
Video 5 - 2 KOLs are featured in, "Targeted Therapies in HR+/HER2- mBC: CAPItello-291"
4 KOLs are featured in this series
4 KOLs are featured in this series
2 KOLs are featured in this program.